- Home
- CFSB vs PLRX Comparison
CFSB vs PLRX Comparison
Compare CFSB & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFSB
- PLRX
- Stock Information
- Founded
- CFSB 1889
- PLRX 2015
- Country
- CFSB United States
- PLRX United States
- Employees
- CFSB N/A
- PLRX N/A
- Industry
- CFSB Major Banks
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CFSB Finance
- PLRX Health Care
- Exchange
- CFSB Nasdaq
- PLRX Nasdaq
- Market Cap
- CFSB 92.5M
- PLRX 93.3M
- IPO Year
- CFSB N/A
- PLRX 2020
- Fundamental
- Price
- CFSB $14.22
- PLRX $1.91
- Analyst Decision
- CFSB
- PLRX Hold
- Analyst Count
- CFSB 0
- PLRX 11
- Target Price
- CFSB N/A
- PLRX $3.93
- AVG Volume (30 Days)
- CFSB 10.0K
- PLRX 966.5K
- Earning Date
- CFSB 10-29-2025
- PLRX 11-07-2025
- Dividend Yield
- CFSB N/A
- PLRX N/A
- EPS Growth
- CFSB N/A
- PLRX N/A
- EPS
- CFSB N/A
- PLRX N/A
- Revenue
- CFSB $7,612,000.00
- PLRX N/A
- Revenue This Year
- CFSB N/A
- PLRX N/A
- Revenue Next Year
- CFSB N/A
- PLRX N/A
- P/E Ratio
- CFSB N/A
- PLRX N/A
- Revenue Growth
- CFSB N/A
- PLRX N/A
- 52 Week Low
- CFSB $6.41
- PLRX $1.10
- 52 Week High
- CFSB $14.24
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- CFSB 60.99
- PLRX 67.67
- Support Level
- CFSB $13.93
- PLRX $1.72
- Resistance Level
- CFSB $14.24
- PLRX $1.91
- Average True Range (ATR)
- CFSB 0.04
- PLRX 0.11
- MACD
- CFSB -0.01
- PLRX 0.04
- Stochastic Oscillator
- CFSB 93.68
- PLRX 100.00
About CFSB CFSB Bancorp Inc.
CFSB Bancorp Inc provides banking services. It offers a variety of financial services to individuals and small businesses through its offices in Quincy, Holbrook, and Weymouth. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending product is residential mortgage loans.The Company's loan portfolio includes residential real estate, commercial real estate, construction, and consumer loan segments. Residential real estate loans include classes for one- to four-family, multi-family, second mortgages and home equity lines of credit.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.